tradingkey.logo

Prelude Therapeutics Inc <PRLD.OQ> expected to post a loss of 47 cents a share - Earnings Preview

ReutersMay 2, 2025 1:01 PM
  • Prelude Therapeutics Inc PRLD.OQ PRLD.O is expected to show no change in quarterly revenue when it reports results on May 5 (estimated) for the period ending March 31 2025

  • ​LSEG's mean analyst estimate for Prelude Therapeutics Inc is for a loss of 47 cents per share.

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."

  • The mean earnings estimate of analysts had risen by about 0.9% in the last three months. ​

  • Wall Street's median 12-month price target for Prelude Therapeutics Inc is $4.50​, above​ its last closing price of $0.92. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.46

-0.38

Beat

18

Sep. 30 2024

-0.47

-0.47

-0.43

Beat

8.9

Jun. 30 2024

-0.43

-0.43

-0.46

Missed

-7​

Mar. 31 2024

-0.48

-0.48

-0.42

Beat

13.4

​​Dec. 31 2023

-0.49

-0.49

-0.46

Beat

6.1

Sep. 30 2023

-0.58

-0.58

-0.45

Beat

22.7​

Jun. 30 2023

-0.64

-0.63

-0.54

Beat

14.7

Mar. 31 2023

-0.69

-0.68

-0.58

Beat

15.3

This summary was machine generated May 2 at 13:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI